- Home
- ACVA vs LIVN Comparison
ACVA vs LIVN Comparison
Compare ACVA & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACVA
- LIVN
- Stock Information
- Founded
- ACVA 2014
- LIVN 1987
- Country
- ACVA United States
- LIVN United Kingdom
- Employees
- ACVA N/A
- LIVN N/A
- Industry
- ACVA Business Services
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ACVA Consumer Discretionary
- LIVN Health Care
- Exchange
- ACVA Nasdaq
- LIVN Nasdaq
- Market Cap
- ACVA 2.5B
- LIVN 2.2B
- IPO Year
- ACVA 2021
- LIVN 1993
- Fundamental
- Price
- ACVA $14.31
- LIVN $35.58
- Analyst Decision
- ACVA Strong Buy
- LIVN Buy
- Analyst Count
- ACVA 11
- LIVN 7
- Target Price
- ACVA $22.73
- LIVN $60.29
- AVG Volume (30 Days)
- ACVA 2.9M
- LIVN 772.6K
- Earning Date
- ACVA 05-07-2025
- LIVN 05-07-2025
- Dividend Yield
- ACVA N/A
- LIVN N/A
- EPS Growth
- ACVA N/A
- LIVN 262.50
- EPS
- ACVA N/A
- LIVN 1.16
- Revenue
- ACVA $637,156,000.00
- LIVN $1,253,437,000.00
- Revenue This Year
- ACVA $23.93
- LIVN $5.79
- Revenue Next Year
- ACVA $23.63
- LIVN $5.35
- P/E Ratio
- ACVA N/A
- LIVN $30.67
- Revenue Growth
- ACVA 32.40
- LIVN 8.66
- 52 Week Low
- ACVA $11.88
- LIVN $32.48
- 52 Week High
- ACVA $23.46
- LIVN $64.48
- Technical
- Relative Strength Index (RSI)
- ACVA 46.94
- LIVN 40.50
- Support Level
- ACVA $13.76
- LIVN $32.65
- Resistance Level
- ACVA $14.71
- LIVN $35.89
- Average True Range (ATR)
- ACVA 1.04
- LIVN 1.91
- MACD
- ACVA 0.16
- LIVN 0.05
- Stochastic Oscillator
- ACVA 68.07
- LIVN 42.70
About ACVA ACV Auctions Inc.
ACV Auctions Inc is a mobile platform for wholesale car auctions. The company provides a digital marketplace for wholesale vehicle transactions and data services that offer transparent and accurate vehicle information for customers.
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.